July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Paolo Tarantino: First Positive Phase 3 Trial for a Bispecific ADC
Jul 3, 2025, 16:01

Paolo Tarantino: First Positive Phase 3 Trial for a Bispecific ADC

Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X by Minhua Chu, Managing Partner at TransitionValue Partner, adding:

“First positive phase 3 trial for a bispecific ADC (EGFR/HER3 topo1 ADC), co-developed by Biokin Pharma and BMS. Bispecific ADCs are coming!”

Quoting Minhua Chu’s post:

“Biokin Pharma (SystImmune) announced that its EGFR/HER3 ADC, iza-bren (BL-B01D1), achieved the primary endpoint in the interim analysis of a Ph3 clinical trial (BL-B01D1-303) for the treatment of nasopharyngeal carcinoma.”

Read further.

Paolo Tarantino: First Positive Phase 3 Trial for a Bispecific ADC

More posts featuring Paolo Tarantino.